Radiotherapy for Canine Apocrine Gland Anal Sac Adenocarcinoma: Survival Outcomes and Side Effects of a Palliative Treatment Protocol of 20 Gy in Five Consecutive Fractions
Open Access
- 15 May 2024
- journal article
- research article
- Published by MDPI AG in Veterinary Sciences
- Vol. 11 (5) , 219
Abstract
This research aims to evaluate the outcomes of a radiotherapy protocol, consisting of five fractions of 4 Gy each, resulting in a total dose of 20 Gy for apocrine gland anal sac tumors and local lymph nodes in canines. This protocol was assessed as a palliative treatment for macroscopic tumors alone, or in combination with additional therapies under different scenarios. Medical records from fifty canine patients met the inclusion criteria and were divided into different treatment groups: radiotherapy alone (n = 22, 44%), radiotherapy with chemotherapy or targeted therapy with toceranib (n = 18, 36%), surgery with radiotherapy (n = 5, 10%), and surgery with radiotherapy and chemotherapy or targeted therapy with toceranib (n = 5, 10%). Patients who received radiotherapy alone had a median survival time of 384 days (95% CI 198–569) and 628 days (95% CI 579–676) for RT + additional therapies. The median time to progression for patients with radiotherapy alone was 337 days (95% CI 282–391 days), and 402 days (95% CI 286–517 days) for radiotherapy plus additional treatments. Acute side effects were mild, with the majority having diarrhea (61%), and only one patient developed grade III late effects VRTOG v2 classification; however, this happened 22 months after the first radiotherapy protocol after re-irradiation. The results demonstrate that radiotherapy alone under this protocol provided a comparable median time to progression vs. radiotherapy plus additional treatments while maintaining acceptable side effects. The combination of this protocol with other treatment modalities offers attractive results for local disease control and survival while maintaining acceptable toxicities. Overall, these findings contribute to the growing evidence supporting the role of radiotherapy in managing apocrine gland anal sac adenocarcinoma in dogs.Keywords
This publication has 33 references indexed in Scilit:
- European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision makingThe Lancet Oncology, 2022
- Canine Apocrine Gland Anal Sac Adenocarcinoma: A ReviewTopics in Companion Animal Medicine, 2022
- How Low Can You Go? The Radiobiology of HypofractionationClinical Oncology, 2022
- The Radiobiology of HypofractionationClinical Oncology, 2015
- Expression of PDGFR‐β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistryVeterinary and Comparative Oncology, 2011
- Three‐dimensional conformal versus non‐graphic radiation treatment planning for apocrine gland adenocarcinoma of the anal sac in 18 dogs (2002–2007)Veterinary and Comparative Oncology, 2011
- Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumoursVeterinary and Comparative Oncology, 2011
- Surgery of Metastatic Anal Sac Adenocarcinoma in Five DogsVeterinary Surgery, 2006
- Postoperative radiotherapy and mitoxantrone for anal sac adenocarcinoma in the dog: 15 cases (1991–2001)Veterinary and Comparative Oncology, 2003
- Long‐term results of reirradiation for patients with recurrent rectal carcinomaCancer, 2002